Corrigendum to “HMGB1 contributes to adriamycin-induced cardiotoxicity via up-regulating autophagy” (Toxicology Letters (2018) 292 (115–122), (S0378427418301735), (10.1016/j.toxlet.2018.04.034));HMGB1 contributes to adriamycin-induced cardiotoxicity via up-regulating autophagy

Toxicology Letters

Volumn 292, Issue , 2018, Pages 115-122

  Luo, Peihua ^a   Zhu, Yi ^a   Chen, Min ^b   Yan, Hao ^a   Yang, Bo ^a   Yang, Xiaochun ^a   He, Qiaojun ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG HOSPITAL   (China)

Author keywords

Adriamycin; Autophagy; Cardiotoxicity; HMGB1; YAP

Indexed keywords

AUTOPHAGY RELATED PROTEIN 7; DOXORUBICIN; HIGH MOBILITY GROUP B1 PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR YAP; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; APOPTOSIS REGULATORY PROTEIN; ATG7 PROTEIN, RAT; HBP1 PROTEIN, RAT; YAP PROTEIN, RAT;

ADRIAMYCIN INDUCED CARDIOTOXICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; CARDIAC MUSCLE CELL; CARDIOTOXICITY; CELL SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE SILENCING; GENETIC TRANSFECTION; HEART VOLUME; HUMAN; HUMAN CELL; IN VITRO STUDY; M MODE ECHOCARDIOGRAPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; RAT; RNA INTERFERENCE; SURVIVAL RATE; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECT; GENETICS; HEART DISEASE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TIME FACTOR; WISTAR RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; AUTOPHAGY-RELATED PROTEIN 7; CARDIOTOXICITY; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HEART DISEASES; HMGB1 PROTEIN; MYOCYTES, CARDIAC; RATS, WISTAR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 85046721159     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2019.12.018     Document Type: Erratum

References (36)

1. Abdel-Daim, M.M., et al. Allicin ameliorates doxorubicin-induced cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis. Cancer Chemother. Pharmacol. 80:4 (2017), 745–753.
2. Abushouk, A.I., et al. Cardioprotective mechanisms of phytochemicals against doxorubicin-induced cardiotoxicity. Biomed. Pharm. 90 (2017), 935–946.
3. Andrassy, M., et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 117:25 (2008), 3216–3226.
4. Bonaldi, T., et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22:20 (2003), 5551–5560.
5. Cao, J., et al. Targeted cancer therapy with a 2-deoxyglucose-based adriamycin complex. Cancer Res. 73:4 (2013), 1362–1373.
6. Chen, S., et al. ANGPTL8 reverses established adriamycin cardiomyopathy by stimulating adult cardiac progenitor cells. Oncotarget 7:49 (2016), 80391–80403.
7. Dalby, K.N., et al. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 6:3 (2010), 322–329.
8. Dirks-Naylor, A.J., The role of autophagy in doxorubicin-induced cardiotoxicity. Life Sci. 93:24 (2013), 913–916.
9. Evankovich, J., et al. High mobility group Box 1 Box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity. J. Biol. Chem. 285:51 (2010), 39888–39897.
10. Gottlieb, R.A., Mentzer, R.M., Autophagy during cardiac stress: joys and frustrations of autophagy. Annu. Rev. Physiol. 72 (2010), 45–59.
11. Hariharan, N., et al. Deacetylation of FoxO by sirt1 plays an essential role in mediating starvation-Induced autophagy in cardiac myocytes. Circ. Res. 107:12 (2010), 1470–1482.
12. Heallen, T., et al. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science 332:6028 (2011), 458–461.
13. Huang, J., et al. Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma. Autophagy 8:2 (2012), 275–277.
14. Kang, R., et al. HMGB1: a novel Beclin 1-binding protein active in autophagy. Autophagy 6:8 (2010), 1209–1211.
15. Koleini, N., Kardami, E., Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity. Oncotarget 8:28 (2017), 46663–46680.
16. Lee, K.H., et al. Enhanced-autophagy by exenatide mitigates doxorubicin-induced cardiotoxicity. Int. J. Cardiol. 232 (2017), 40–47.
17. Li, W., et al. Role of HMGB1 in cardiovascular diseases. Curr. Opin. Pharmacol. 6:2 (2006), 130–135.
18. Li, X., et al. Expression profile of apoptotic and proliferative proteins in hypoxic HUVEC treated with statins. Int. J. Oncol. 46:2 (2015), 677–684.
19. Lin, Z., et al. Pi3kcb links Hippo-YAP and PI3K-AKT signaling pathways to promote cardiomyocyte proliferation and survival. Circ. Res. 116:1 (2015), 35–45.
20. Matsui, Y., et al. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ. Res. 100:6 (2007), 914–922.
21. Nathwani, R.A., et al. Serum alanine aminotransferase in skeletal muscle diseases. Hepatology 41:2 (2005), 380–382.
22. Octavia, Y., et al. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J. Mol. Cell. Cardiol. 52:6 (2012), 1213–1225.
23. Scaffidi, P., et al. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418:6894 (2002), 191–195.
24. Shi, Y. Moon, et al. Mechanisms and management of doxorubicin cardiotoxicity. Herz 36:4 (2011), 296–305.
25. Tacar, O., et al. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J. Pharm. Pharmacol. 65:2 (2013), 157–170.
26. Takemura, G., Fujiwara, H., Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog. Cardiovasc. Dis. 49:5 (2007), 330–352.
27. Tang, D., et al. Endogenous HMGB1 regulates autophagy. J. Cell Biol. 190:5 (2010), 881–892.
28. Tsung, A., et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J. Exp. Med. 201:7 (2005), 1135–1143.
29. Vejpongsa, P., Yeh, E.T., Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J. Am. Coll. Cardiol. 64:9 (2014), 938–945.
30. Xie, Z., et al. AMP-activated protein kinase modulates cardiac autophagy in diabetic cardiomyopathy. Autophagy 7:10 (2011), 1254–1255.
31. Xu, H., et al. Endogenous HMGB1 contributes to ischemia-reperfusion-induced myocardial apoptosis by potentiating the effect of TNF-α/JNK. Am. J. Physiol. 300:3 (2011), H913–21.
32. Xue, L.Y., et al. Atg7 deficiency increases resistance of MCF-7 human breast cancer cells to photodynamic therapy. Autophagy 6:2 (2010), 248–255.
33. Yan, X.X., et al. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 205:2 (2009), 544–548.
34. Yan, G., et al. Protein-L-isoaspartate (D-aspartate) O-methyltransferase protects cardiomyocytes against hypoxia induced apoptosis through inhibiting proapoptotic kinase Mst1. Int. J. Cardiol. 168:4 (2013), 3291–3299.
35. Zhao, B., et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21:21 (2007), 2747–2761.
36. Zhao, B., et al. The hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr. Opin. Cell Biol. 20:6 (2008), 638–646.